Literature DB >> 15892632

The Application of Photofrin II as a sensitizing agent for ionizing radiation--a new approach in tumor therapy?

M Schaffer1, B Ertl-Wagner, P M Schaffer, U Kulka, G Jori, E Dühmke, A Hofstetter.   

Abstract

Radiosensitizers represent an enticing concept in tumor therapy. As ionizing radiation affects both neoplastic and normal tissues, its effects are generally non-specific. The aim of applying a radiosensitizing agent is to achieve a maximum effect on tumor tissue, while minimizing the damage to normal tissues. A variety of parameters such as the oxygen supply and the state in the cell cycle, need to be taken into account when evaluating a potential radiosensitizer. Most of the previously known radiosensitizers are neither selective nor tumor specific. In this article, we review the properties and radiosensitizing potential of Photofrin II. Photofrin II is well-known as a photosensitizing agent in photodynamic therapy. In recent years, a radiosensitizing potential of the substance has been demonstrated, specifically increasing the sensitivity of solid tumor tissues, especially of radio-resistant, hypoxic tumor cells, to radiation. This radiosensitizing effect has been demonstrated both by in vitro studies and by animal experiments. Several studies with tissue cultures have demonstrated a radiosensitizing effect of Photofrin II in glioblastoma (U-373MG) and bladder cancer cell lines (RT-4). No effect was noted in colon carcinoma cell lines (HT-29). Unpublished data of additional cell lines will be mentioned in the review. Animal experiments with Lewis sarcoma and with bladder cancer have moreover demonstrated an in vivo effect of Photofrin II as a radiosensitizer. The mechanism of this radiosensitizing effect is not completely understood. In vitro data, however, support the hypothesis that the radiosensitizing action involves OH-radicals in addition to a potential impairment of repair mechanisms after sublethal damage of ionizing radiation. Moreover, early results of a phase I trial are available and document the potential feasibility of the application of Phototofrin II as a radiosensitizing agent in clinical practice.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15892632     DOI: 10.2174/0929867053764653

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  9 in total

1.  Mechanisms in photodynamic therapy: Part three-Photosensitizer pharmacokinetics, biodistribution, tumor localization and modes of tumor destruction.

Authors:  Ana P Castano; Tatiana N Demidova; Michael R Hamblin
Journal:  Photodiagnosis Photodyn Ther       Date:  2005-08-10       Impact factor: 3.631

2.  Treatment of astrocytoma grade III with Photofrin II as a radiosensitizer. A case report.

Authors:  M Schaffer; A Hofstetter; B Ertl-Wagner; R Batash; J Pöschl; P M Schaffer
Journal:  Strahlenther Onkol       Date:  2013-10-26       Impact factor: 3.621

Review 3.  Nanoscintillator conjugates as photodynamic therapy-based radiosensitizers: calculation of required physical parameters.

Authors:  Nicole Y Morgan; Gabriela Kramer-Marek; Paul D Smith; Kevin Camphausen; Jacek Capala
Journal:  Radiat Res       Date:  2009-02       Impact factor: 2.841

4.  Porfimer-sodium (Photofrin-II) in combination with ionizing radiation inhibits tumor-initiating cell proliferation and improves glioblastoma treatment efficacy.

Authors:  Liat Benayoun; Moshe Schaffer; Rotem Bril; Svetlana Gingis-Velitski; Ehud Segal; Alexsander Nevelsky; Ronit Satchi-Fainaro; Yuval Shaked
Journal:  Cancer Biol Ther       Date:  2012-10-31       Impact factor: 4.742

Review 5.  Enhancement of Photodynamic Cancer Therapy by Physical and Chemical Factors.

Authors:  Mingying Yang; Tao Yang; Chuanbin Mao
Journal:  Angew Chem Int Ed Engl       Date:  2019-07-10       Impact factor: 15.336

6.  Investigation of combined photodynamic and radiotherapy effects of gallium phthalocyanine chloride on MCF-7 breast cancer cells.

Authors:  Sara Mayahi; Ali Neshasteh-Riz; Majid Pornour; Samira Eynali; Alireza Montazerabadi
Journal:  J Biol Inorg Chem       Date:  2019-10-25       Impact factor: 3.358

7.  Photophysical Properties of Protoporphyrin IX, Pyropheophorbide-a and Photofrin® in Different Conditions.

Authors:  Bauyrzhan Myrzakhmetov; Philippe Arnoux; Serge Mordon; Samir Acherar; Irina Tsoy; Céline Frochot
Journal:  Pharmaceuticals (Basel)       Date:  2021-02-09

8.  5-Aminolevulinic acid overcomes hypoxia-induced radiation resistance by enhancing mitochondrial reactive oxygen species production in prostate cancer cells.

Authors:  Takuya Owari; Nobumichi Tanaka; Yasushi Nakai; Makito Miyake; Satoshi Anai; Shingo Kishi; Shiori Mori; Rina Fujiwara-Tani; Yudai Hojo; Takuya Mori; Masaomi Kuwada; Tomomi Fujii; Masatoshi Hasegawa; Kiyohide Fujimoto; Hiroki Kuniyasu
Journal:  Br J Cancer       Date:  2022-04-01       Impact factor: 9.075

Review 9.  Combinatorial Therapeutic Approaches with Nanomaterial-Based Photodynamic Cancer Therapy.

Authors:  Yang Hao; Chih Kit Chung; Zhenfeng Yu; Ruben V Huis In 't Veld; Ferry A Ossendorp; Peter Ten Dijke; Luis J Cruz
Journal:  Pharmaceutics       Date:  2022-01-04       Impact factor: 6.321

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.